GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 8,746 Shares

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 8,746 shares of the stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $95.61, for a total transaction of $836,205.06. Following the completion of the sale, the chief financial officer now owns 15,996 shares in the company, valued at approximately $1,529,377.56. This trade represents a 35.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The stock was sold at an average price of $96.71, for a total value of $362,565.79.
• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The shares were sold at an average price of $90.05, for a total value of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The shares were sold at an average price of $94.72, for a total transaction of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total transaction of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total value of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total value of $108,737.20.

GeneDx Stock Down 4.5 %

Shares of NASDAQ WGS traded down $3.98 during trading hours on Tuesday, hitting $84.59. The company had a trading volume of 860,363 shares, compared to its average volume of 646,225. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The firm's 50 day moving average is $87.87 and its 200-day moving average is $75.16. GeneDx Holdings Corp. has a 1-year low of $8.53 and a 1-year high of $115.60. The stock has a market capitalization of $2.37 billion, a P/E ratio of -43.16 and a beta of 1.91.

Remove Ads

GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The company had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. On average, analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. MCF Advisors LLC lifted its holdings in GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after purchasing an additional 182 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in shares of GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock worth $27,000 after buying an additional 316 shares during the period. Global Retirement Partners LLC acquired a new position in GeneDx in the 4th quarter valued at about $28,000. Lazard Asset Management LLC bought a new position in GeneDx in the 4th quarter valued at about $35,000. Finally, Comerica Bank acquired a new stake in GeneDx during the fourth quarter worth approximately $50,000. 61.72% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on WGS shares. The Goldman Sachs Group raised their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. TD Cowen raised their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.